Monocarboxylate transporter 1 (MCT1) facilitates the transport of monocarboxylate fuels (lactate, pyruvate and ketone bodies) and acidic drugs, such as valproic acid, across cell membranes. We recently reported that MCT1 is deficient on microvessels in the epileptogenic hippocampal formation in patients with medicationrefractory temporal lobe epilepsy (TLE). To further define the role of MCT1 in the pathophysiology of TLE, we used immunohistochemistry and stereological analysis to localize and quantify the transporter in the hippocampal formation in three novel and highly relevant rat models of TLE and in nonepileptic control animals. One model utilizes methionine sulfoximine to induce brain glutamine synthetase deficiency and recurrent limbic seizures, while two models employ an episode of perforant pathway stimulation to cause epilepsy. MCT1 was lost on microvessels and upregulated on astrocytes in the hippocampal formation in all models of TLE. Notably, the loss of MCT1 on microvessels was not due to a reduction in microvessel density. The similarities in MCT1 expression among human subjects with TLE and several animal models of the disease strongly suggest a critical role of this molecule in the pathogenesis of TLE. We hypothesize that the downregulation of MCT1 may promote seizures via impaired uptake of ketone bodies and antiepileptic drugs by the epileptogenic brain. We also propose that the overexpression of MCT1 on astrocytes may lead to increased uptake or release of monocarboxylates by these cells, with important implications for brain metabolism and excitability. These hypotheses can now be rigorously tested in several animal models that replicate key features of human TLE.
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Introduction
Temporal lobe epilepsy (TLE), which is characterized by spontaneous recurrent seizures that involve limbic brain areas such as the hippocampal formation, remains one of the most common types of medication-refractory epilepsies in humans (Hauser et al., 1993; Spencer, 2002) . Even though more than 10 new antiepileptic drugs have been approved for use in the United States since the early 1990s, approximately one-third of all patients with TLE cannot control their seizures despite aggressive pharmacotherapy. More efficacious therapies against TLE are therefore needed, and a better understanding of the mechanism of the disease is likely to facilitate the development of such therapies.
We recently reported that monocarboxylate transporter 1 (MCT1) is deficient on the endothelial cell membrane of microvessels in the epileptogenic hippocampal formation in patients with medicationrefractory TLE (Lauritzen et al., 2011) . The deficiency is most pronounced in patients with TLE and concomitant hippocampal sclerosis, which is characterized by glial proliferation and loss of neurons, particularly in CA1, CA3 and the dentate hilus of the hippocampal formation (Gloor, 1991; Sommer, 1880) . MCT1 facilitates the transport of monocarboxylates, including lactate, pyruvate, acetoacetate and betahydroxybutyrate, across the blood-brain barrier (Bergersen et al., 1999; Cornford et al., 1982; Cremer et al., 1976; Gerhart et al., 1997; Jackson et al., 1995; Koehler-Stec et al., 1998; Leino et al., 1999; Pellerin et al., 1998; Pierre et al., 2000; Price et al., Neurobiology of Disease 45 (2012) 
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